We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Affymetrix and NimbleGen Systems Enter into Licensing Agreement

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Affymetrix and NimbleGen Systems Enter into Licensing Agreement "

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Affymetrix Inc. and NimbleGen Systems Inc. have announced that NimbleGen has obtained a non-exclusive, worldwide license to a number of Affymetrix patents covering the manufacture, use and sales of nucleic acid microarrays and related products and services in the research field. 

"This licensing agreement with NimbleGen follows from a commercial relationship and enables both companies to better serve customers within the growing microarray market," said Alan Sherr, vice president and chief counsel for Licensing at Affymetrix.

"Since the inception of our licensing program, Affymetrix has signed many agreements that validate our position as the clear market innovator and leader. We look forward to the continued expansion of this program."

"This license is a major milestone in NimbleGen's evolution as a company, and part of a fundamental expansion of our commercial strategy," said Stan Rose, Ph.D., president and CEO of NimbleGen.

"Our intent is to expand dramatically the ability of scientists to access NimbleGen products and services."